La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

IDEXX Laboratories Gestion

Gestion contrôle des critères 3/4

Le PDG IDEXX Laboratories' est Jay Mazelsky, nommé en Jun2019, a un mandat de 5.17 ans. La rémunération annuelle totale est $ 11.52M, composée du salaire de 8.7% et des bonus 91.3%, y compris les actions et options de la société. détient directement 0.099% des actions de la société, d'une valeur de € 36.51M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 5.2 ans et 7.8 ans.

Informations clés

Jay Mazelsky

Directeur général

US$11.5m

Rémunération totale

Pourcentage du salaire du PDG	8.7%
Durée du mandat du directeur général	5.3yrs
Propriété du PDG	0.1%
Durée moyenne d'occupation des postes de direction	5.3yrs
Durée moyenne du mandat des membres du conseil d'administration	7.9yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Jay Mazelsky a-t-elle évolué par rapport aux bénéfices de IDEXX Laboratories?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2024	n/a	n/a	US$846m
Mar 31 2024	n/a	n/a	US$867m
Dec 31 2023	US$12m	US$1m	US$845m
Sep 30 2023	n/a	n/a	US$823m
Jun 30 2023	n/a	n/a	US$791m
Mar 31 2023	n/a	n/a	US$699m
Dec 31 2022	US$10m	US$1m	US$679m
Sep 30 2022	n/a	n/a	US$670m
Jun 30 2022	n/a	n/a	US$664m
Mar 31 2022	n/a	n/a	US$735m
Dec 31 2021	US$9m	US$977k	US$745m
Sep 30 2021	n/a	n/a	US$757m
Jun 30 2021	n/a	n/a	US$728m
Mar 31 2021	n/a	n/a	US$674m
Dec 31 2020	US$7m	US$814k	US$582m
Sep 30 2020	n/a	n/a	US$497m
Jun 30 2020	n/a	n/a	US$460m
Mar 31 2020	n/a	n/a	US$437m
Dec 31 2019	US$7m	US$632k	US$428m
Sep 30 2019	n/a	n/a	US$423m
Jun 30 2019	n/a	n/a	US$407m
Mar 31 2019	n/a	n/a	US$390m
Dec 31 2018	US$3m	US$555k	US$377m
Sep 30 2018	n/a	n/a	US$330m
Jun 30 2018	n/a	n/a	US$307m
Mar 31 2018	n/a	n/a	US$284m
Dec 31 2017	US$2m	US$469k	US$263m

Rémunération vs marché: La rémunération totale de Jay ($USD 11.52M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché Austrian ($USD 4.47M ).

Rémunération et revenus: La rémunération de Jay a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Jay Mazelsky (63 yo)

5.3yrs

Titularisation

US$11,519,309

Compensation

Mr. Jonathan J. Mazelsky, also known as Jay, serves as Independent Director at DENTSPLY SIRONA Inc. since May 24, 2023. He has been President, Chief Executive Officer and Director at IDEXX Laboratories, In...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Jonathan Mazelsky	President	5.3yrs	US$11.52m	0.099% $ 36.4m
Brian McKeon	CFO, Executive VP & Treasurer	10.7yrs	US$3.85m	0.060% $ 21.8m
Michael Lane	Executive VP and GM of Reference Laboratories & Information Technology	4.7yrs	US$2.92m	0.0086% $ 3.1m
John Hart	Senior Vice President of Global Operations	7yrs	pas de données	pas de données
Jeffery Chadbourne	Senior Vice President of Commercial Finance & Sales Operations	9.7yrs	pas de données	pas de données
Martin Smith	Executive VP & CTO	3.1yrs	pas de données	pas de données
Ken Grady	Senior VP & Chief Information Officer	8.6yrs	pas de données	pas de données
Sharon Underberg	Executive VP	no data	US$1.88m	0.0068% $ 2.5m
Michael Johnson	Executive VP & Chief Human Resources Officer	2.5yrs	pas de données	0.00022% $ 80.6k
George Fennell	Senior VP & Chief Revenue Officer	no data	pas de données	0.0084% $ 3.1m
Michael Erickson	Executive VP and GM of Point of Care Diagnostics & Telemedicine	no data	pas de données	0.013% $ 4.7m
Murthy Yerramilli	Senior Vice President of Research & Development	4.7yrs	pas de données	pas de données

5.3yrs

Durée moyenne de l'emploi

55yo

Âge moyen

Gestion expérimentée: L'équipe de direction de IDXX est chevronnée et expérimentée (ancienneté moyenne 5.2 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Jonathan Mazelsky	President	4.9yrs	US$11.52m	0.099% $ 36.4m
M. Szostak	Independent Director	12.2yrs	US$367.66k	0.0074% $ 2.7m
Daniel Junius	Independent Director	10.5yrs	US$362.66k	0.0031% $ 1.1m
Bruce Claflin	Independent Director	9.2yrs	US$367.66k	0.0021% $ 766.1k
Jonathan Ayers	Non-Employee Director	22.7yrs	US$335.16k	0.70% $ 257.3m
Stuart Essig	Independent Director	7.2yrs	US$350.16k	0.0024% $ 879.7k
Lawrence Kingsley	Independent Non-Executive Chairman	7.9yrs	US$495.02k	0.0096% $ 3.5m
Sophie Vandebroek	Independent Director	11.2yrs	US$335.16k	0.011% $ 4.0m
Irene Chang Britt	Independent Director	1.2yrs	US$258.89k	0.00025% $ 91.6k
Sam Samad	Independent Director	5.2yrs	US$342.66k	0% $ 0
Asha Collins	Independent Director	3.8yrs	US$335.16k	0.00095% $ 348.2k

7.9yrs

Durée moyenne de l'emploi

62yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de IDXX sont considérés comme expérimentés (ancienneté moyenne 7.8 ans).

IDEXX Laboratories Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

IDEXX Laboratories, Inc., Annual General Meeting, May 06, 2024

IDEXX Laboratories, Inc. Announces Retirement of James F. Polewaczyk, Executive Vice President and Chief Commercial Officer, Effective April 1, 2024

Insufficient new directors

Executive VP & Chief Commercial Officer recently sold €2.8m worth of stock

IDEXX Laboratories, Inc. Announces the Election of Irene Chang Britt as an Independent Class I Director and as an Independent Member of Audit Committee and Compensation and Talent Committee

Independent Director recently sold €862k worth of stock

Recent updates

IDEXX Laboratories, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Second quarter 2024 earnings released: EPS: US$2.46 (vs US$2.70 in 2Q 2023)

IDEXX Laboratories, Inc. Revises Earnings Guidance for the Year 2024

IDEXX Laboratories, Inc. to Report Q2, 2024 Results on Aug 06, 2024

IDEXX Laboratories, Inc., Annual General Meeting, May 06, 2024

First quarter 2024 earnings released: EPS: US$2.84 (vs US$2.58 in 1Q 2023)

Idexx Laboratories, Inc. Revises Earnings Guidance for 2024

Full year 2023 earnings released: EPS: US$10.17 (vs US$8.12 in FY 2022)

Idexx Launches Vellotm, an Innovative Pet Owner Engagement Software Solution, Streamlining How Practices and Clients Connect

IDEXX Laboratories, Inc. to Report Q1, 2024 Results on May 02, 2024

IDEXX Laboratories, Inc. Provides Financial Guidance for 2024

Full year 2023 earnings released: EPS: US$10.17 (vs US$8.12 in FY 2022)

Now 27% overvalued after recent price rise

New major risk - Share price stability

IDEXX Laboratories, Inc. Announces Retirement of James F. Polewaczyk, Executive Vice President and Chief Commercial Officer, Effective April 1, 2024

Insufficient new directors

IDEXX Laboratories, Inc. Expands Snap Platform with Leish 4Dx Test to Support Veterinarians Globally in Diagnosing Vector-Borne Diseases

New minor risk - Share price stability

Third quarter 2023 earnings released: EPS: US$2.55 (vs US$2.17 in 3Q 2022)

IDEXX Laboratories, Inc. Provides Financial Guidance for 2023

IDEXX Laboratories, Inc. to Report Q4, 2023 Results on Feb 05, 2024

Executive VP & Chief Commercial Officer recently sold €2.8m worth of stock

IDEXX Laboratories, Inc. to Report Q3, 2023 Results on Nov 01, 2023

IDEXX Laboratories, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings released: EPS: US$2.70 (vs US$1.57 in 2Q 2022)

IDEXX Laboratories, Inc. Announces the Election of Irene Chang Britt as an Independent Class I Director and as an Independent Member of Audit Committee and Compensation and Talent Committee

IDEXX Laboratories, Inc. Announces Novel Diagnostic Test for Kidney Injury, Expanding the Veterinary Industry's Most Comprehensive Renal Testing Portfolio

Independent Director recently sold €862k worth of stock

First quarter 2023 earnings released: EPS: US$2.58 (vs US$2.30 in 1Q 2022)

IDEXX Laboratories, Inc. to Report Q1, 2023 Results on May 02, 2023

Full year 2022 earnings released: EPS: US$8.12 (vs US$8.74 in FY 2021)

IDEXX Laboratories, Inc. Provides Earnings Guidance for the Full Year 2023

Insufficient new directors

IDEXX Laboratories, Inc. to Report Q4, 2022 Results on Feb 06, 2023

Third quarter 2022 earnings released: EPS: US$2.17 (vs US$2.06 in 3Q 2021)

Insufficient new directors

IDEXX Laboratories, Inc. Provides Earnings Guidance for the Full Year 2022

Second quarter 2022 earnings released: EPS: US$1.57 (vs US$2.37 in 2Q 2021)

IDEXX Laboratories, Inc. Provides Earnings Guidance for the Year 2022

Investor sentiment deteriorated over the past week

IDEXX Laboratories, Inc. to Report Q2, 2022 Results on Aug 02, 2022

First quarter 2022 earnings released: EPS: US$2.30 (vs US$2.39 in 1Q 2021)

IDEXX Laboratories, Inc., Annual General Meeting, May 11, 2022

IDEXX Laboratories, Inc. to Report Q1, 2022 Results on May 04, 2022

Senior Advisor & Director recently sold €112k worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

IDEXX Laboratories, Inc. Provides Earnings Guidance for the Year 2022

IDEXX Laboratories, Inc. Announces Series of Product and Service Enhancements That Enable Veterinary Practices to Be More Efficient While Managing Increasing Patient Volumes

Investor sentiment deteriorated over the past week

Executive VP & Chief Commercial Officer recently sold €2.6m worth of stock

Third quarter 2021 earnings released: EPS US$2.06 (vs US$1.71 in 3Q 2020)

President recently sold €3.4m worth of stock

Insider recently sold €6.0m worth of stock

Second quarter 2021 earnings released: EPS US$2.37 (vs US$1.75 in 2Q 2020)

IDEXX Laboratories, Inc.(NasdaqGS:IDXX) dropped from Russell 1000 Dynamic Index

IDEXX Laboratories, Inc. (NasdaqGS:IDXX) acquired ezyVet.

Chief Marketing Officer & Senior VP recently sold €916k worth of stock

Chief Marketing Officer & Senior VP recently sold €1.3m worth of stock

Independent Director has left the company

Senior Advisor & Director recently sold €227k worth of stock

First quarter 2021 earnings released: EPS US$2.39 (vs US$1.31 in 1Q 2020)

IDEXX Laboratories, Inc. Raises Earnings Guidance for 2021

Independent Director recently sold €135k worth of stock

New 90-day high: €452

Dr. Rebecca M. Henderson Intends to Retire from the Board of Directors of IDEXX Laboratories, Inc

Independent Director recently sold €4.9m worth of stock

Full year 2020 earnings released: EPS US$6.82 (vs US$4.97 in FY 2019)

Revenue beats expectations

New 90-day high: €424

IDEXX Laboratories, Inc. and the Tuskegee University College of Veterinary Medicine Announce Initiative